AMENDMENT NUMBER 1 TO DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT
This Amendment to Development, License, Supply Agreement (the
"Amendment") is entered into as of the 4th day of September 1998 between Elan
Corporation plc, a corporation organized under the laws of Ireland ("Elan") and
Schein Pharmaceutical, Inc., a Delaware corporation ("Schein").
Introduction
A. Elan and Schein entered into a Development, License and Supply
Agreement, dated March 31, 1998 (the "Agreement").
B. The parties wish to amend the Agreement in accordance with the terms
of this Amendment.
NOW, THEREFORE, in consideration of the mutual covenants and promises
herein contained, and for other good and valuable consideration, it is agreed as
follows:
1. Definitions and Incorporation. Unless otherwise defined, all terms
used herein shall have the meaning ascribed to them in the Agreement, and the
terms and provisions of the Agreement are incorporated herein by reference as
though set forth in full.
2. Patent Strategy/Patent Determination.
(a) Section 3.2.2 of the Agreement is hereby deleted in its entirety
and replaced by the following:
"Schein shall report to Xxxx Xxxxxx'x decision that
Schein believes the Product(s) are non-infringing
within a period of not more than 180 days from the
Effective Date; provided, however, that on a Product
by Product basis, Elan shall not unreasonably withhold
its consent to a request by Schein to extend the
period in which Schein is required to report such
decision by an additional 30 days (thereby requiring
Schein to report to Xxxx Xxxxxx'x decision that Schein
believes the Product(s) are non-infringing within a
period of 210 days from the Effective Date). Elan and
Schein shall prioritize the order in which the
Products are to be reviewed;"
(b) The second sentence of Section 3.2.4 of the Agreement is
hereby deleted in its entirety and replaced by the following:
"All such decisions will be finalized no later than
180 days from the Effective Date; provided, however,
that on a Product by Product basis, Elan shall not
unreasonably withhold its consent to a request by
Schein to extend the period in which all such
decisions will be finalized by an additional 30 days
(thereby requiring all such decisions to be finalized
no later than 210 days from the Effective Date)."
3. Reaffirmation of the Agreement and Other Documents. Except as
modified herein, all of the covenants, terms and conditions of the Agreement,
and all documents, instruments and agreements executed in conjunction therewith
remain in full force and effect and are hereby ratified and reaffirmed in all
respects. In the event of any conflict, inconsistency or incongruity between the
terms and conditions of this Amendment and the covenants, terms and conditions
of the Agreement or any documents, instruments or agreements executed in
conjunction therewith, the terms and conditions of this Amendment shall govern
and control.
4. Counterparts. This Amendment may be executed in two or more
counterparts, each of which together shall constitute an original but which,
when taken together, shall constitute but one instrument.
IN WITNESS WHEREOF, this Amendment is executed as of the day and year
first above written.
ELAN CORPORATION, PLC
By: /s/ Xxxxx X. Xxxxxx
-------------------------------
Name: Xxxxx X. Xxxxxx
-------------------------------
Title: Chief Executive Officer
------------------------------
SCHEIN PHARMACEUTICAL, INC.
By: /s/ Xxxx Xxxxxxxxx
------------------------------
Name: Xxxx Xxxxxxxxx
------------------------------
Title: SVP, Strategic Development
------------------------------
2
